SRU Biosystems, a leader in highly sensitive labeled and label-free detection technologies, today announced the issuance of their 30th patent in the field of label-free optical biosensors and instrumentation. The patent, US 7,371,562, includes claims for optical biosensors and their use in a wide variety of assay formats, including the detection of substances in unpurified biological samples. The patent adds to the expansive coverage that the Company has secured for its core technologies, including its instrumentation, microplate designs, and product applications.
“The issuance of the 30th patent is part our ongoing strategy for the Company to protect its broad intellectual property in the field of optical biosensors,” said Richard W. Wagner, Ph.D., President and CEO of SRU Biosystems. “This patent broadly covers our technology and its use with unpurified biological samples to detect a wide array of binding events, such as antibody-antigen or protein-small molecule interactions.”
Dr. Wagner continued, “During the past six months, 7 additional patents have issued that cover our instruments, biosensor manufacturing, and microplate biosensors. In addition, we have also had 3 patents issue with claims that cover different assay formats, such as self-referencing in the same biosensor well, well inserts for containing cells apart from the biosensor, and direct label-free detection of substrate cleavage on the sensor, for example, by a protease. The issuance of these broad claims continues to establish our vast position in this field.”
The patent is related to the SRU BIND® technology, which includes instrumentation such as the Cartridge Reader (for 8- and 16-well biosensors), BIND® 96/384 Reader TURBO, capable of 96- and 384-well microplate detection, and the recently introduced BIND® 384/1536 Reader TURBO, with its first-in-class 1536-well label-free detection capacity. The SRU BIND® Reader can be easily integrated into automated systems and represents one of the most cost-effective solutions for high throughput label-free detection on the market for antibody and small molecule/fragment screening, and cell-based applications.
About SRU Biosystems
SRU Biosystems, Inc., is a life science company developing novel technologies for rapidly analyzing the interactions of large genomic, protein, peptide, antibody or small molecule compound libraries against a wide range of biochemical targets. SRU is incorporating its technology into microtiter plates, microarray slides and other industry standard formats to create sensitive and high throughput tools that can be used to answer important biological questions for biomedical research, pharmaceutical drug discovery and diagnostics. www.srubiosystems.com
Contacts:
Brant Binder, CFO, +1 781-933-7255, ext. 202
Bbinder@srubiosystems.com
or
MacDougall
Biomedical Communications
Jennifer Greenleaf, +1 781-235-3060
